TY - JOUR AU - Li, Xingzhe D. AU - Simone II, Charles B. PY - 2019 TI - The inflammatory response from stereotactic body proton therapy versus stereotactic body radiation therapy: implications from early stage non-small cell lung cancer JF - Annals of Translational Medicine; Vol 7, Supplement 8 (December 31, 2019): Annals of Translational Medicine Y2 - 2019 KW - N2 - Lung cancer is the second most common noncutaneous cancer and the deadliest cancer in the United States (US) with 228,150 estimated new cases in 2019 (1). About 87% of lung cancers diagnosed in the US are non-small cell lung cancer (NSCLC), which currently has a 5-year overall survival (OS) rate of 23% across all stages, ranging from 57% for stage I to 4% for stage IV diseases (2). UR - https://atm.amegroups.org/article/view/31814